Business · 21/08/2002Updated: 10/17/2026 · 1 min read
FDA Releases Draft Guidance for Liposome Drug Products
The Food and Drug Administration (FDA) has made available a draft guidance document outlining recommendations for the chemistry, manufacturing, and controls, human pharmacokinetics and bioavailability, and labeling documentation for liposome drug products in new drug applications (NDAs).
Original source language: Federal Register — Food and Drug AdministrationOpen original release →